Metabolic syndrome in rheumatoid arthritis

Abstract

Insulin resistance is an essential feature of the metabolic syndrome that has been linked to rheumatoid arthritis (RA). Understanding how inflammation arising in one tissue affects the physiology and pathology of other organs remains an unanswered question with therapeutic implications for chronic conditions including obesity, diabetes mellitus, atherosclerosis, and RA. Adipokines may play a role in the development of atherogenesis in patients with RA. Biologic therapies, such as TNF-∝ antagonists, that block proinflammatory cytokines have beneficial effects on the insulin resistance that is often observed in patients with RA.